$90M Financing Fuels LeonaBio's Acquisition of Phase 3 Breast Cancer Drug
LONA has more than doubled off its 52-week low of $3.6.
Summary
LeonaBio announced a significant business update, including a $90 million private placement financing and the acquisition of an exclusive global license for lasofoxifene, a Phase 3 selective estrogen receptor modulator (SERM) for breast cancer. This substantial financing, which is approximately equal to the company's current market capitalization, provides critical capital to advance the newly acquired late-stage lasofoxifene program and its ATH-1105 ALS program. This capital raise follows the recent 8-K where stockholders approved a substantial increase in authorized common stock, enabling this dilutive but transformative financing. The acquisition of a Phase 3 asset significantly bolsters LeonaBio's pipeline and strategic focus, positioning it for potential multi-billion dollar opportunities. Traders will closely monitor the progress of the Phase 3 ELAINE-3 trial for lasofoxifene, with enrollment expected to complete in Q4 2026 and topline data in 2H 2027, as well as the initiation of the ATH-1105 Phase 2 study in 2H 2026.
At the time of this announcement, LONA was trading at $9.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90.4M. The 52-week trading range was $3.60 to $50.74. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.